Our President and Managing Director, Ms. Jennifer Che, gave a talk at the LSPN Spring 2024 at Boston about strategies for protecting therapeutics in China, touching upon topics like PTE, patent linkage, data exclusivity, how to deal with IP arising in China, and a very interesting recent case in China about semaglutide (Ozempic/Wegovy) that highlighted the nuanced differences in what kind of post filing data can be accepted by the China patent office.

Jennifer enjoyed “talking shop” with so many different patent attorneys from all over bringing their own diverse perspectives, with all the connections made at such a great conference.

我们的过去活动

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by Managing IP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

2025年6月11日

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Recommended Insights

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日
There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]
阅读更多 >

Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case

2023年11月27日
Each year, China’s Supreme People’s Court (SPC) issues its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in the previous year. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]
阅读更多 >

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
阅读更多 >

China Announcing More Proposed Amendments to the Examination Guidelines in 2022

2022年11月17日
It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published[1], this time consolidating the […]
阅读更多 >
Top crossarrow-right